



**Shipment to:**

Kinderspital Zürich  
Laborzentrum für Hämatologie  
Steinwiesstrasse 75  
CH-8032 Zürich

**Contact:**

Cytomorphology: 044 266 75 99  
Immunphenotyping/FCM-MRD: 044 266 31 10  
Moleculargenetics/PCR-MRD: 044 266 75 74  
Cytogenetics: 044 266 78 49

**Laboratory Shipment Form for Leukemia**

**Patient**

Name: \_\_\_\_\_  
First name: \_\_\_\_\_  
Date of birth: \_\_\_\_\_

**Sender**

Address: \_\_\_\_\_  
  
Treating physician: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Collection date: \_\_\_\_\_

**Diagnosis (suspected diagnosis)**

Therapy protocol:

- AIEOP-BFM ALL 2017
- IntReALL SR 2010 / ALL Relapse
- IntReALL HR 2010
- EsPhALL2017/COGAALL1631
- Pediatric Relapsed AML 2010/01
- other: \_\_\_\_\_

Date of initial diagnosis: \_\_\_\_\_

- Under treatment:  yes /  no
- Pretreatment:  Transfusions  Neupogen
- Therapy timepoint: \_\_\_\_\_

**Diagnostics / Follow-up diagnostics** (see following pages, please enclose required pages)

Laboratory values: Please enclose copy of lab report

Leukocytes _____ G/L	Liquor cell count: _____
Erythrocytes _____ T/L	Nucleated cells _____ / $\mu$ L
Hemoglobin _____ g/L	Erythrocytes LQ _____ / $\mu$ L
Thrombocytes _____ G/L	Macroscop. contaminated with blood? <input type="checkbox"/> yes / <input type="checkbox"/> no

**Material**

- |  |   |
|--|---|
| <input type="checkbox"/> Blood smears (6 unstained)  | <input type="checkbox"/> Liquor (2 cytopsins unstained) |
| <input type="checkbox"/> Bone marrow smears (6-8 unstained)  | <input type="checkbox"/> Heparin-blood                  |
| Puncture site: _____   | <input type="checkbox"/> EDTA-blood                     |
| <input type="checkbox"/> Heparin-bone marrow   | <input type="checkbox"/> other: _____                   |
| (ideally 3x 5ml in tubes without beads and gel, if possible please perform puncture at 2 sites in the bone through the same puncture site in the skin) |   |

## Accompanying note AIEOP-BFM ALL 2017

AIEOP-BFM ALL 2017	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenetics
<b>All patients</b>				
<input type="checkbox"/> initial	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> day 8	PB smears			
<input type="checkbox"/> day 15	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 33 (TP 1)	BM smears		Heparin-BM	
<input type="checkbox"/> day 78/92 (TP 2)	BM smears*		Heparin-BM**	
<b>non-HR</b>				
<input type="checkbox"/> before protocol II	BM smears*		Heparin-BM*	
<b>HR</b>				
<input type="checkbox"/> after HR-1 (TP HR1)	BM smears*		Heparin-BM	
<input type="checkbox"/> after HR-2 (TP HR2)	BM smears*		Heparin-BM	
<input type="checkbox"/> after HR-3 (TP HR3)	BM smears*		Heparin-BM	
<input type="checkbox"/> after DNX-FLA (TP D/F)	BM smears*		Heparin-BM	
<input type="checkbox"/> before protocol III <input type="checkbox"/> 1. <input type="checkbox"/> 2. <input type="checkbox"/> 3.	BM smears*		Heparin-BM	
<input type="checkbox"/> before SZT	BM smears*		Heparin-BM	
<input type="checkbox"/> other timepoint:				
<b>Randomized treatment arms:</b>				
<b>R-eHR (pB-ALL)</b>				
<input type="checkbox"/> day 64 Consol Bext (TP1a)	BM smears*		Heparin-BM	
<b>R-HR (pB-ALL)</b>				
<b>Control arm</b>				
<input type="checkbox"/> after HR-2 (TP HR2)	BM smears*		Heparin-BM	
<input type="checkbox"/> after HR-3 (TP HR3)	BM smears*		Heparin-BM	
<b>Experimental arm</b>				
<input type="checkbox"/> start Blina Cycle 1 (TP HR Blina d1)	BM smears*	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 15 Blina Cycle (TP HR Blina d15)	BM smears*		Heparin-BM	
<input type="checkbox"/> day 29 Blina Cycle 1 (TP HR Blina1 d29)	BM smears*	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 29 Blina Cycle 2 (TP HR Blina2 d29)	BM smears*	Heparin-BM	Heparin-BM	
<b>R-MR (pB-ALL)</b>				
<input type="checkbox"/> before protocol II (TP3)	BM smears*+		Heparin-BM*+	
<b>Control arm</b>				
<input type="checkbox"/> start Maintenance (TP MR contr. 1)	BM smears*+		Heparin-BM*+	
<input type="checkbox"/> day 29 Maintenance (TP MR contr. 2)	BM smears*+		Heparin-BM*+	
<b>Experimental arm</b>				
<input type="checkbox"/> start Blina Cycle (TP MR Blina d1)	BM smears*+	Heparin-BM*+	Heparin-BM*+	
<input type="checkbox"/> day 29 Blina Cycle (TP MR Blina d29)	BM smears*+	Heparin-BM*+	Heparin-BM*+	
<b>R-T (T-ALL)</b>				
<input type="checkbox"/> day 57 Protocol IB/2 (TP1b)	BM smears*			

\* Sample will not be analyzed routinely. Asservation only, if nothing else requested.

\*\* Sample will be analyzed in case of PCR-MRD positivity at day 33 (TP1). Otherwise asservation only, if nothing else requested.

\*+ Sample will be analyzed in case of PCR-MRD positivity on TP2. Otherwise asservation only, if nothing else requested.

## Accompanying note IntReALL SR 2010 (a) / Epratuzumab PD (b)

### (a)

IntReALL SR 2010	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenetics
<input type="checkbox"/> relapse diagnosis	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> week 3 (Arm A/B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 5 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 6 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 9 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 10 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 13 (Arm A/B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 15 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 16 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> after SCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

### (b)

IntReALL SR 2010 Epratuzumab PD (CD22) *	SR-A	SR-B
3ml Heparin blood:		
<input type="checkbox"/> week 5	X	
<input type="checkbox"/> week 6		X
<input type="checkbox"/> week 7	X	
<input type="checkbox"/> week 8		X
<input type="checkbox"/> week 9	X	
<input type="checkbox"/> week 10		X
<input type="checkbox"/> week 11	X	
<input type="checkbox"/> week 12		X
<input type="checkbox"/> week 13	X	
<input type="checkbox"/> week 14		X
<input type="checkbox"/> week 15	X	
<input type="checkbox"/> week 16		X
<input type="checkbox"/> week 17	X	
<input type="checkbox"/> week 18		X
<input type="checkbox"/> week 23	X	
<input type="checkbox"/> week 24		X
<input type="checkbox"/> week 29	X	
<input type="checkbox"/> week 30		X

\* at all CD22-measurement timepoints IgG-levels have to be determined locally

### Accompanying note IntReALL HR 2010

IntReALL HR 2010	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenetics
<input type="checkbox"/> relapse diagnosis	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> week 5 (before HC1)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 8 (before HC2)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> week 11 (before HC3)	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> before SCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

### Accompanying note EsPhALL2017/COGAALL1631

EsPhALL2017/COGAALL1631	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenetics
<input type="checkbox"/> Initial	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> after protocol IB	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> after Consolidation 3	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> before SCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

## Accompanying note AML BFM 2012 (Treatment protocol)

AML BFM 2012	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenetics
<input type="checkbox"/> initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM	Heparin-BM
after induction 1 (day 21-28)				
<input type="checkbox"/> after ADxE	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> after CDxA	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> SR <input type="checkbox"/> IR <input type="checkbox"/> HR				
before induction 2				
<input type="checkbox"/> AI	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> HAM	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> HAM Sorafenib	BM smears	Heparin-BM	Heparin-BM	
before course 3				
<input type="checkbox"/> haM	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> AI	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> AI Sorafenib	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> haM	BM smears	Heparin-BM	Heparin-BM	
before course 4				
<input type="checkbox"/> HAE	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> haM	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> haM Sorafenib	BM smears	Heparin-BM	Heparin-BM	
before course 5				
<input type="checkbox"/> HAE	BM smears		Heparin-BM	
<input type="checkbox"/> HAE Sorafenib	BM smears		Heparin-BM	
<input type="checkbox"/> before SCT	BM smears		Heparin-BM	
<input type="checkbox"/> MRD Monitoring*			Heparin blood*	
time point:			Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*

\* In patients with molecular markers, MRD monitoring is recommended every 4 weeks starting after the 6<sup>th</sup> month (after diagnosis) until the 18<sup>th</sup> month.

## Accompanying note Relapsed AML 2010/01

Pediatric Relapsed AML 2010/01	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenetics
<input type="checkbox"/> initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM	Heparin-BM
<input type="checkbox"/> day 21	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 28	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> day 42-56	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> before SCT	BM smears	Heparin-BM	Heparin-BM	
<input type="checkbox"/> other timepoint:	*	*	*	*